Last reviewed 2026-04-20 · How we verify

Chinicine (VIQUIDIL)

Phase 2 active Small molecule

Chinicine (generic name: VIQUIDIL) is a viquidil drug. It is currently in Phase 2 development.

Viquidil works by interacting with a specific biological pathway to produce its therapeutic effect.

Viquidil, a small molecule drug in the viquidil class, is a medication with unknown target and commercial status. Its mechanism of action is not publicly disclosed. No approved indications or pharmacokinetic data are available. Further information is required to provide a comprehensive summary.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	VIQUIDIL
Drug class	viquidil
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Unfortunately, the exact mechanism of action of Viquidil is not publicly available, making it difficult to explain how it works. However, in general, small molecule drugs like Viquidil are designed to bind to specific proteins or receptors in the body, altering their function and leading to a therapeutic effect. This can help to restore balance to the body's natural processes and alleviate symptoms of a particular condition.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Chinicine CI brief — competitive landscape report
Chinicine updates RSS · CI watch RSS

Frequently asked questions about Chinicine

What is Chinicine?

Chinicine (VIQUIDIL) is a viquidil drug.

How does Chinicine work?

Viquidil works by interacting with a specific biological pathway to produce its therapeutic effect.

What is the generic name of Chinicine?

VIQUIDIL is the generic (nonproprietary) name of Chinicine.

What drug class is Chinicine in?

Chinicine belongs to the viquidil class. See all viquidil drugs at /class/viquidil.

What development phase is Chinicine in?

Chinicine is in Phase 2.

Drug class: All viquidil drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing